S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.52 (-0.27%)
NVDA   817.98 (-3.39%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.84 (-0.06%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   149.63 (-2.16%)
CGC   7.96 (+1.66%)
DIS   111.75 (-0.60%)
AMC   3.20 (+9.59%)
PFE   25.79 (+1.58%)
PYPL   62.05 (-0.08%)
XOM   120.26 (+1.47%)
S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.52 (-0.27%)
NVDA   817.98 (-3.39%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.84 (-0.06%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   149.63 (-2.16%)
CGC   7.96 (+1.66%)
DIS   111.75 (-0.60%)
AMC   3.20 (+9.59%)
PFE   25.79 (+1.58%)
PYPL   62.05 (-0.08%)
XOM   120.26 (+1.47%)
S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.52 (-0.27%)
NVDA   817.98 (-3.39%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.84 (-0.06%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   149.63 (-2.16%)
CGC   7.96 (+1.66%)
DIS   111.75 (-0.60%)
AMC   3.20 (+9.59%)
PFE   25.79 (+1.58%)
PYPL   62.05 (-0.08%)
XOM   120.26 (+1.47%)
S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.52 (-0.27%)
NVDA   817.98 (-3.39%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.84 (-0.06%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   149.63 (-2.16%)
CGC   7.96 (+1.66%)
DIS   111.75 (-0.60%)
AMC   3.20 (+9.59%)
PFE   25.79 (+1.58%)
PYPL   62.05 (-0.08%)
XOM   120.26 (+1.47%)
Free Trial
OTCMKTS:INTI

Inhibitor Therapeutics (INTI) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)
Free INTI Stock Alerts
$0.07
0.00 (0.00%)
(As of 04/18/2024 ET)
Compare
Today's Range
$0.07
▼
$0.07
50-Day Range
$0.05
▼
$0.08
52-Week Range
$0.01
▼
$0.30
Volume
N/A
Average Volume
8,914 shs
Market Capitalization
$11.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest
INTI stock logo

About Inhibitor Therapeutics Stock (OTCMKTS:INTI)

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.

INTI Stock Price History

INTI Stock News Headlines

April 15, 2024 | finance.yahoo.com
Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Pipeline Research Report 2024: Drugs in Development, Therapeutics Scenario and Growth Prospects
April 8, 2024 | msn.com
Saruparib demonstrates early efficacy in breast cancers with DNA repair defects in Phase I/II trial
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
April 3, 2024 | finance.yahoo.com
Watchmaker Genomics Announces Launch of Cost-effective RNase Inhibitor for Single-cell, Single-nuclei, and Pathogen Detection Applications
March 14, 2024 | finance.yahoo.com
Janus Kinase (JAK) Inhibitor Market Forecast 2024-2034: Analyzes Trends Likely to Shape Future Opportunities
March 14, 2024 | finance.yahoo.com
Exploring the FcRn Inhibitor Market Landscape, 2024: Market Insights, Pipeline Analysis, Expert Perspectives, and Future Trends to 2034
January 10, 2024 | seekingalpha.com
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
January 10, 2024 | tmcnet.com
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
December 19, 2023 | finance.yahoo.com
Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board
December 13, 2023 | finance.yahoo.com
Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University
December 4, 2023 | tmcnet.com
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
November 14, 2023 | markets.businessinsider.com
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity
November 7, 2023 | finance.yahoo.com
Cardurion Pharmaceuticals to Provide Update on CaMKII Inhibitor Program at the American Heart Association’s Scientific Sessions 2023
October 16, 2023 | businesswire.com
Antiverse and GlobalBio, Inc. Extend Collaboration to Advance Antibody Cancer Therapeutics
September 5, 2023 | benzinga.com
Nykode Therapeutics Announces FDA Approval of IND for VB-C-04, a Trial of VB10.16 in HPV16-Positive Cervical Cancer
May 18, 2023 | finanznachrichten.de
Trueline Therapeutics Inc.: Trueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810
May 18, 2023 | businesswire.com
Trueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810
May 17, 2023 | marketwatch.com
Corrosion Inhibitor for Oil and Gas Market | Worldwide Industry Trends 2023-2030
May 17, 2023 | marketwatch.com
Wax Inhibitor Market 2023 Fastest Growing Industry in Advanced Material Market by 2030
April 20, 2023 | wsj.com
Inhibitor Therapeutics Inc.
April 4, 2023 | msn.com
Oncternal Therapeutics Announces Strategic Reprioritization, Stops Two Zilovertamab Studies
April 4, 2023 | uk.finance.yahoo.com
iOmx Therapeutics Announces Dosing of First Patient with SIK Inhibitor OMX-0407 in Phase I Clinical Trial
March 31, 2023 | marketwatch.com
2023-2029 Medical FLT3 Inhibitor Market Share and Growth Insights | Latest Research Report
March 25, 2023 | marketwatch.com
Norepinephrine Reuptake Inhibitor Market Share by 2031
March 24, 2023 | marketwatch.com
Proton Pump Inhibitor Drug Market with Latest Technology Estimate up to 2030
March 24, 2023 | marketwatch.com
PAA Scale Inhibitor Market Top Players By 2031
See More Headlines
Receive INTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/29/2024
Today
4/19/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:INTI
CUSIP
N/A
CIK
1042418
Web
www.inhibitortx.com
Phone
(888) 841-6811
Fax
813-527-0500
Employees
3
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-3,030,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-45.51%
Return on Assets
-30.61%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.46
Quick Ratio
13.46

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.03 per share
Price / Book
2.28

Miscellaneous

Outstanding Shares
171,970,000
Free Float
164,057,000
Market Cap
$11.78 million
Optionable
Not Optionable
Beta
-0.84
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Francis E. O'Donnell Jr. (Age 74)
    M.D., Founder, Executive Chairman & CEO
    Comp: $600k
  • Mr. James A. McNulty CPA (Age 74)
    Interim CFO, Treasurer & Secretary
    Comp: $205.4k

Key Competitors

View All Competitors

INTI Stock Analysis - Frequently Asked Questions

How have INTI shares performed in 2024?

Inhibitor Therapeutics' stock was trading at $0.0920 at the beginning of 2024. Since then, INTI stock has decreased by 25.5% and is now trading at $0.0685.
View the best growth stocks for 2024 here.

Are investors shorting Inhibitor Therapeutics?

Inhibitor Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 500 shares, an increase of 400.0% from the March 15th total of 100 shares. Based on an average daily volume of 37,200 shares, the short-interest ratio is currently 0.0 days.
View Inhibitor Therapeutics' Short Interest.

When is Inhibitor Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our INTI earnings forecast.

How were Inhibitor Therapeutics' earnings last quarter?

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) announced its earnings results on Friday, March, 29th. The company reported ($0.01) earnings per share (EPS) for the quarter.

How do I buy shares of Inhibitor Therapeutics?

Shares of INTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:INTI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
How Biden has already won 2024
Porter & Company
Top 5 AI Stocks to Buy for 2024
Market Moving Trends